Lineage Cell Therapeutics, Inc. (TLV:LCTX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 567.50
-1.30 (-0.23%)
Mar 9, 2026, 5:24 PM IDT
Lineage Cell Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -63.53 | -18.61 | -21.49 | -26.27 | -43.02 | Upgrade
|
| Depreciation & Amortization | 0.7 | 0.61 | 0.69 | 0.73 | 0.87 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.01 | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | 14.84 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.04 | -0.22 | -0.5 | 1.69 | -3.73 | Upgrade
|
| Stock-Based Compensation | 4.75 | 5.08 | 4.64 | 4.29 | 3.72 | Upgrade
|
| Other Operating Activities | 28.3 | -1.21 | -1.11 | 2.01 | -2.28 | Upgrade
|
| Change in Accounts Receivable | -0.32 | 0.11 | -0.45 | 50.31 | -0.86 | Upgrade
|
| Change in Accounts Payable | 2.27 | -1.68 | -2.3 | -18.7 | 21.65 | Upgrade
|
| Change in Unearned Revenue | -6.11 | -7.68 | -7.65 | -13.35 | 0.38 | Upgrade
|
| Change in Other Net Operating Assets | 0.05 | 0.49 | -0.42 | 0.45 | -0.07 | Upgrade
|
| Operating Cash Flow | -18.92 | -23.09 | -28.57 | 1.06 | -23.56 | Upgrade
|
| Capital Expenditures | -0.52 | -0.57 | -0.67 | -0.41 | -0.34 | Upgrade
|
| Divestitures | - | - | - | - | 0.02 | Upgrade
|
| Investment in Securities | -12.94 | -1.74 | 47.12 | -45.75 | 10.06 | Upgrade
|
| Investing Cash Flow | -13.46 | -2.31 | 46.45 | -46.16 | 9.75 | Upgrade
|
| Long-Term Debt Repaid | -0.06 | -0.05 | -0.05 | -0.03 | -0.02 | Upgrade
|
| Net Debt Issued (Repaid) | -0.06 | -0.05 | -0.05 | -0.03 | -0.02 | Upgrade
|
| Issuance of Common Stock | 27.71 | 36.11 | 6.51 | 0.8 | 38.11 | Upgrade
|
| Repurchase of Common Stock | -0.02 | -0.02 | -0.04 | -0.02 | -0.05 | Upgrade
|
| Other Financing Activities | -0.68 | -0.17 | - | 0.89 | -1.1 | Upgrade
|
| Financing Cash Flow | 26.95 | 35.86 | 6.42 | 1.63 | 36.93 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.4 | -0.1 | -0.25 | -0.87 | -0.02 | Upgrade
|
| Net Cash Flow | -5.03 | 10.36 | 24.06 | -44.34 | 23.09 | Upgrade
|
| Free Cash Flow | -19.44 | -23.66 | -29.24 | 0.65 | -23.9 | Upgrade
|
| Free Cash Flow Margin | -133.56% | -249.05% | -326.89% | 4.39% | -550.59% | Upgrade
|
| Free Cash Flow Per Share | -0.08 | -0.12 | -0.17 | 0.00 | -0.14 | Upgrade
|
| Cash Interest Paid | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Levered Free Cash Flow | -11.18 | -12.8 | -10.37 | 13.34 | -37.46 | Upgrade
|
| Unlevered Free Cash Flow | -11.18 | -12.8 | -10.37 | 13.34 | -37.46 | Upgrade
|
| Change in Working Capital | -4.11 | -8.77 | -10.8 | 18.7 | 21.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.